A Phase 3 interventional study of Ibuprofen 600 mg Immediate Release/Extended Release Caplet in Analgesia, sponsored by Pfizer. Completed at 18 sites in United States. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-08-28.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A self-selection and actual use trial to evaluate the extent to which consumers will appropriately select and use the 600 mg immediate release/extended release caplets and comply with dosing instructions.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Ibuprofen 600 mg Immediate Release/Extended Release Caplet
Drug page: Ibuprofen
Ibuprofen 600 mg Immediate Release/Extended Release Caplet to be adminstered orally (i.e., one caplet every 12 hours, not to exceed 2 caplets per day) for pain.
Percentage of Participants Who Correctly Select to Use or Correctly De-select Not to Use Ibuprofen 600 Milligram (mg) Immediate Release (IR) or Extended Release (ER) Study Medication
Participants as correct selectors included all participants who selected Ibuprofen 600 mg IR/ER medication with the last episode of pain of \>=6 hours, if left untreated. Participants as correct de-selectors included all participants who either selected Ibuprofen 200 mg or selected 'neither' with a typical pain duration of less than (\<) 6 hours, if left untreated.
Time frame: Day 1
Percentage of Participants Who Correctly Select to Use or Correctly De-select Not to Use Ibuprofen 600 mg IR/ER Study Medication Excluding Those Classified as Missed Opportunity
Participants as correct selectors included all participants who selected Ibuprofen 600 mg IR/ER medication with the last episode of pain of \>=6 hours, if left untreated. Participants as correct de-selectors included all participants who either selected Ibuprofen 200 mg or selected 'neither' with a typical pain duration of \<6 hours, if left untreated. Participants were classified as "missed opportunity" cases when they selected the Ibuprofen 200 mg IR medication with their typical duration of pain \>=6 hours.
Time frame: Day 1
Percentage of Participants Who Select to Use Ibuprofen 600 mg IR/ER Medication With a Typical Pain Duration of Less Than (<) 6 Hours
Percentage of participants with correct selection of Ibuprofen 600 mg IR/ER medication with a typical duration of pain \<6 hours were reported in this outcome measure.
Time frame: Day 1
Percentage of Participants Who Select to Use Ibuprofen 200 mg IR Medication With a Typical Pain Duration of Greater Than or Equal to (>=) 6 Hours
Percentage of participants with selection of Ibuprofen 200 mg IR medication with a typical duration of pain \>=6 hours were reported in this outcome measure. These participants were classified as ''missed opportunity'' cases.
Time frame: Day 1
Percentage of Participants With the Use of Study Medication For Greater Than (>) 10 Days With an Average Daily Dose of Greater Than (>) 1600 mg
Percentage of participants with the use of study medication for \>10 days with an average daily dose of \>1600 mg were reported in this outcome measure.
Time frame: Day 1 up to Day 30
Percentage of Participants With the Use of Study Medication For Less Than or Equal to (<=) 10 Days and Use More Than 20 Tablets With an Average Daily Dose of Greater Than (>) 1600 mg
Percentage of participants who used the study medication for \<=10 days and used more than 20 tablets with an average daily dose of \>1600 mg were reported in this outcome measure.
Time frame: Day 1 up to Day 30
Average Daily Dose Among Excessive Users
Excessive users included all participants who used the study medication for more than 10 days (not necessarily consecutive) during study period with an average daily dose of \>1600 mg or all participants who used the study medication for \<=10 days during study period, used more than 20 tablets and had an average daily dose of \>1600 mg.
Time frame: Day 1 up to Day 30
Number of Dosing Days Among Inappropriate Users
Participants were considered as inappropriate users if they improperly used the study medication in their last pain episode duration of \<6 hours, if left untreated, based on the information provided at the follow up interview.
Time frame: Day 1 up to Day 30
Number of Pain Episodes Treated With Single Dose or Multiple Dose Among Inappropriate Users
In this outcome measure, number of pain episodes treated with single dose or multiple dose per day among inappropriate users were reported. Participants were considered as inappropriate users if they improperly used the study medication in their last pain episode duration of \<6 hours, based on the information provided at the follow up interview.
Time frame: Day 1 up to Day 30
Number of Treatment Days Exceeding the Daily Dose of 1200 Milligram
Number of treatment days when participants exceeded the daily dose of 1200 milligram were reported in this outcome measure.
Time frame: Day 1 up to Day 30
Number of Treatment Days Exceeding the Daily Dose of 1200 Milligram Excluding Treatment of Severe Symptoms
In this outcome measure, number of treatment days exceeding the daily dose of 1200 mg, excluding the days when severe symptoms were treated, were reported.
Time frame: Day 1 up to Day 30
Number of Dosing Occasions Exceeding the Single Dose of 600 Milligram
In this outcome measure, number of dosing occasions exceeding the single dose of 600 mg were reported.
Time frame: Day 1 up to Day 30
Number of Dosing Occasions Exceeding the Single Dose of 600 Milligram Excluding Treatment of Severe Symptoms
In this outcome measure, number of dosing occasions exceeding the single dose of 600 mg, excluding the events when severe symptoms were treated, were reported.
Time frame: Day 1 up to Day 30
Average Daily Dose of Study Medication
Time frame: Day 1 up to Day 30
Maximum Daily Dose of Study Medication
Time frame: Day 1 up to Day 30
| Milestone | Self-Selection Arm | Compliance Arm |
|---|---|---|
| Started | 251 | 832 |
| Completed | 228 | 382 |
| Not completed | 23 | 450 |
| Withdrew: Participant not purchased the product | 0 | 20 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Ineligible | 6 | 2 |
| Withdrew: Administrative reasons | 17 | 6 |
| Withdrew: No study medication taken | 0 | 1 |
| Withdrew: Protocol violation | 0 | 55 |
| Withdrew: Adverse event | 0 | 3 |
| Withdrew: Lost to follow-up | 0 | 14 |
| Withdrew: Ineligible or not willing to continue | 0 | 348 |
Participants as correct selectors included all participants who selected Ibuprofen 600 mg IR/ER medication with the last episode of pain of \>=6 hours, if left untreated. Participants as correct de-selectors included all participants who either selected Ibuprofen 200 mg or selected 'neither' with a typical pain duration of less than (\<) 6 hours, if left untreated.
| percentage of participants | Self-Selection Arm |
|---|---|
| Percentage of Participants Who Correctly Select to Use or Correctly De-select Not to Use Ibuprofen 600 Milligram (mg) Immediate Release (IR) or Extended Release (ER) Study Medication | 69.1 (63.3 to 74.8) |
Participants as correct selectors included all participants who selected Ibuprofen 600 mg IR/ER medication with the last episode of pain of \>=6 hours, if left untreated. Participants as correct de-selectors included all participants who either selected Ibuprofen 200 mg or selected 'neither' with a typical pain duration of \<6 hours, if left untreated. Participants were classified as "missed opportunity" cases when they selected the Ibuprofen 200 mg IR medication with their typical duration of pain \>=6 hours.
| percentage of participants | Self-Selection Arm |
|---|---|
| Percentage of Participants Who Correctly Select to Use or Correctly De-select Not to Use Ibuprofen 600 mg IR/ER Study Medication Excluding Those Classified as Missed Opportunity | 82.7 (77.6 to 87.8) |
Percentage of participants with correct selection of Ibuprofen 600 mg IR/ER medication with a typical duration of pain \<6 hours were reported in this outcome measure.
| percentage of participants | Self-Selection Arm |
|---|---|
| Percentage of Participants Who Select to Use Ibuprofen 600 mg IR/ER Medication With a Typical Pain Duration of Less Than (<) 6 Hours | 63.2 (47.8 to 78.5) |
Percentage of participants with selection of Ibuprofen 200 mg IR medication with a typical duration of pain \>=6 hours were reported in this outcome measure. These participants were classified as ''missed opportunity'' cases.
| percentage of participants | Self-Selection Arm |
|---|---|
| Percentage of Participants Who Select to Use Ibuprofen 200 mg IR Medication With a Typical Pain Duration of Greater Than or Equal to (>=) 6 Hours | 20.9 (15.4 to 26.3) |
Percentage of participants with the use of study medication for \>10 days with an average daily dose of \>1600 mg were reported in this outcome measure.
| percentage of participants | Compliance Arm |
|---|---|
| Percentage of Participants With the Use of Study Medication For Greater Than (>) 10 Days With an Average Daily Dose of Greater Than (>) 1600 mg | 1.2 (0.2 to 2.3) |
Percentage of participants who used the study medication for \<=10 days and used more than 20 tablets with an average daily dose of \>1600 mg were reported in this outcome measure.
| percentage of participants | Compliance Arm |
|---|---|
| Percentage of Participants With the Use of Study Medication For Less Than or Equal to (<=) 10 Days and Use More Than 20 Tablets With an Average Daily Dose of Greater Than (>) 1600 mg | 0 (0 to 0) |
Excessive users included all participants who used the study medication for more than 10 days (not necessarily consecutive) during study period with an average daily dose of \>1600 mg or all participants who used the study medication for \<=10 days during study period, used more than 20 tablets and had an average daily dose of \>1600 mg.
| milligram | Compliance Arm |
|---|---|
| Average Daily Dose Among Excessive Users | 1821.1 ± 157.4 |
Participants were considered as inappropriate users if they improperly used the study medication in their last pain episode duration of \<6 hours, if left untreated, based on the information provided at the follow up interview.
| days | Compliance Arm |
|---|---|
| Number of Dosing Days Among Inappropriate Users | 14.8 ± 8.1 |
In this outcome measure, number of pain episodes treated with single dose or multiple dose per day among inappropriate users were reported. Participants were considered as inappropriate users if they improperly used the study medication in their last pain episode duration of \<6 hours, based on the information provided at the follow up interview.
| pain episodes | Compliance Arm |
|---|---|
| Single dose | 13.1 ± 7.4 |
| Multiple dose | 1.8 ± 2.6 |
Number of treatment days when participants exceeded the daily dose of 1200 milligram were reported in this outcome measure.
| days | Compliance Arm |
|---|---|
| Number of Treatment Days Exceeding the Daily Dose of 1200 Milligram | 0.31 ± 1.188 |
In this outcome measure, number of treatment days exceeding the daily dose of 1200 mg, excluding the days when severe symptoms were treated, were reported.
| days | Compliance Arm |
|---|---|
| Number of Treatment Days Exceeding the Daily Dose of 1200 Milligram Excluding Treatment of Severe Symptoms | 0.12 ± 0.637 |
In this outcome measure, number of dosing occasions exceeding the single dose of 600 mg were reported.
| dosing occasions | Compliance Arm |
|---|---|
| Number of Dosing Occasions Exceeding the Single Dose of 600 Milligram | 1.48 ± 4.185 |
In this outcome measure, number of dosing occasions exceeding the single dose of 600 mg, excluding the events when severe symptoms were treated, were reported.
| dosing occasions | Compliance Arm |
|---|---|
| Number of Dosing Occasions Exceeding the Single Dose of 600 Milligram Excluding Treatment of Severe Symptoms | 0.83 ± 3.020 |
| milligram | Compliance Arm |
|---|---|
| Average Daily Dose of Study Medication | 781.0 ± 229.3 |
| milligram | Compliance Arm |
|---|---|
| Maximum Daily Dose of Study Medication | 1147.9 ± 604.43 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Compliance Arm | — | 1/405 (0.2%) | 163/405 (40.2%) |
| Event | Compliance Arm |
|---|---|
| Pleural infectionInfections and infestations | 1/405 |
| Event | Compliance Arm |
|---|---|
| NasopharyngitisInfections and infestations | 59/405 |
| ToothacheGastrointestinal disorders | 26/405 |
| Back painMusculoskeletal and connective tissue disorders | 15/405 |
| MyalgiaMusculoskeletal and connective tissue disorders | 12/405 |
| HeadacheNervous system disorders | 10/405 |
| Abdominal pain upperGastrointestinal disorders | 6/405 |
| SinusitisInfections and infestations | 6/405 |
| Ligament sprainInjury, poisoning and procedural complications | 6/405 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 6/405 |
| Tension headacheNervous system disorders | 6/405 |
Analysis population included all the participants who were randomized in the study.
| Age, Customized(participants) | Self-Selection Arm | Compliance Arm | Total |
|---|---|---|---|
| Less Than (<)18 years | 2 | 5 | 7 |
| Greater Than or Equal to (>=) 18 years | 247 | 827 | 1074 |
| Unknown | 2 | 0 | 2 |
| Sex/Gender, Customized(participants) | Self-Selection Arm | Compliance Arm | Total |
|---|---|---|---|
| Female | 114 | 408 | 522 |
| Male | 114 | 403 | 517 |
| Unknown | 23 | 21 | 44 |
Plan to share: Yes — Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests
Ran from Sep 2012 to primary completion in Jun 2013, 8 months.
Results were first posted in Aug 2017, 4 years 2 months after primary completion. A results delay was requested in Jul 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibuprofen
Agnosia